Evidence connecting old, new and neglected glucose-lowering drugs to bile acid-induced GLP-1 secretion: A review

Diabetes, Obesity and Metabolism

Volumn 19, Issue 9, 2017, Pages 1214-1222

  Kårhus, Martin L ^a   Brønden, Andreas ^a   Sonne, David P ^a   Vilsbøll, Tina ^a,b   Knop, Fillip K ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

antidiabetic drug; ASBT inhibitors, bile acid, bile acid sequestrants, drug mechanism; GLP 1; incretin therapy; metformin; type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; APICAL SODIUM BILE ACID COTRANSPORTER INHIBITOR; BIGUANIDE DERIVATIVE; BILE ACID; BILE ACID SEQUESTRANT; CHENODEOXYCHOLIC ACID; COLESEVELAM; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ELOBIXIBAT; G PROTEIN COUPLED RECEPTOR; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; GLUCOSE DERIVATIVE; INCRETIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; TAKEDA G PROTEIN COUPLED RECEPTOR 5; UNCLASSIFIED DRUG; GASTROINTESTINAL AGENT;

COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DIGESTION; DRUG ACTIVITY; ENERGY EXPENDITURE; FLATULENCE; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; GLUCOSE METABOLISM; HORMONE ACTION; HORMONE RELEASE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID ANALYSIS; LIPID ASSIMILATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; BLOOD; COMPARATIVE STUDY; DRUG EFFECTS; ENTEROENDOCRINE CELL; EVIDENCE BASED MEDICINE; HYPERGLYCEMIA; HYPOGLYCEMIA; METABOLISM; SECRETION (PROCESS);

ANIMALS; BILE ACIDS AND SALTS; DIABETES MELLITUS, TYPE 2; ENTEROENDOCRINE CELLS; EVIDENCE-BASED MEDICINE; GASTROINTESTINAL AGENTS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MODELS, BIOLOGICAL;

EID: 85027862697     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12946     Document Type: Review

References (74)

1. King RJ, Grant PJ. Diabetes and cardiovascular disease: pathophysiology of a life-threatening epidemic. Herz. 2016;41(3):184-192.
2. Thomas C, Pellicciari R, Pruzanski M, et al. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov. 2008;7(8):678-693.
3. Sonne DP, Hansen M, Knop FK. Bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretion. Eur J Endocrinol. 2014;171(2):R47-R65.
4. Bahne E, Hansen M, Bronden A, et al. Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metformin. Diabetes Obes Metab. 2016;18(10):955-961.
5. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-1439.
6. Jorsal T, Rhee NA, Pedersen J, et al. Characterizing the distribution of enteroendocrine cells in patients with type 2 diabetes and non-diabetic controls [abstract]. Diabetes. 2015;64(S1):2054-P.
7. Knop FK, Vilsboll T, Hojberg PV, et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes. 2007;56(8):1951-1959.
8. Vilsboll T, Agerso H, Krarup T, et al. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab. 2003;88(1):220-224.
9. Larsen PJ, Holst JJ. Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. Regul Pept. 2005;128(2):97-107.
10. Hansen L, Deacon CF, Orskov C, et al. Glucagon-like peptide-1-(7–36)amide is transformed to glucagon-like peptide-1-(9–36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology. 1999;140(11):5356-5363.
11. Nakagawa A, Satake H, Nakabayashi H, et al. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci. 2004;110(1):36-43.
12. Balkan B, Li X. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol. 2000;279(4):R1449-R1454.
13. Imeryuz N, Yegen BC, Bozkurt A, et al. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol. 1997;273(4, pt 1):G920-G927.
14. Gribble FM, Williams L, Simpson AK, et al. A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes. 2003;52(5):1147-1154.
15. Tolhurst G, Heffron H, Lam YS, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 2012;61(2):364-371.
16. Carr RD, Larsen MO, Winzell MS, et al. Incretin and islet hormonal responses to fat and protein ingestion in healthy men. Am J Physiol. 2008;295(4):E779-E784.
17. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819-837.
18. Wu T, Little TJ, Bound MJ, et al. A protein preload enhances the glucose-lowering efficacy of vildagliptin in type 2 diabetes. Diabetes Care. 2016;39(4):511-517.
19. Hofmann AF, Hagey LR. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci. 2008;65(16):2461-2483.
20. Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev. 2003;83(2):633-671.
21. Wheeler HO. Concentrating function of the gallbladder. Am J Med. 1971;51(5):588-595.
22. Hofmann AF. Chronic diarrhea caused by idiopathic bile acid malabsorption: an explanation at last. Expert Rev Gastroenterol Hepatol. 2009;3(5):461-464.
23. Adrian TE, Gariballa S, Parekh KA, et al. Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers. Diabetologia. 2012;55(9):2343-2347.
24. Brighton CA, Rievaj J, Kuhre RE, et al. Bile acids trigger GLP-1 release predominantly by accessing basolaterally located G protein-coupled bile acid receptors. Endocrinology. 2015;156(11):3961-3970.
25. Broeders EP, Nascimento EB, Havekes B, et al. The bile acid chenodeoxycholic acid increases human brown adipose tissue cctivity. Cell Metab. 2015;22(3):418-426.
26. Trabelsi MS, Daoudi M, Prawitt J, et al. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat Commun. 2015;6:7629.
27. Wu T, Bound MJ, Standfield SD, et al. Effects of rectal administration of taurocholic acid on glucagon-like peptide-1 and peptide YY secretion in healthy humans. Diabetes Obes Metab. 2013;15(5):474-477.
28. Hansen M, Scheltema MJ, Sonne DP, et al. The effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion. Diabetes Obes Metab. 2016;18(6):571-580.
29. Kumar DP, Asgharpour A, Mirshahi F, et al. Activation of transmembrane bile acid receptor TGR5 modulates pancreatic islet alpha cells to promote glucose homeostasis. J Biol Chem. 2016;291(13):6626-6640.
30. Knop FK. Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes? Am J Physiol. 2010;299(1):E10-E13.
31. Kumar DP, Rajagopal S, Mahavadi S, et al. Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic beta cells. Biochem Biophys Res Commun. 2012;427(3):600-605.
32. Duboc H, Tache Y, Hofmann AF. The bile acid TGR5 membrane receptor: from basic research to clinical application. Dig Liver Dis. 2014;46(4):302-312.
33. Vettorazzi JF, Ribeiro RA, Borck PC, et al. The bile acid TUDCA increases glucose-induced insulin secretion via the cAMP/PKA pathway in pancreatic beta cells. Metabolism. 2016;65(3):54-63.
34. Rohde U, Sonne DP, Christensen M, et al. Cholecystokinin-induced gallbladder emptying and metformin elicit additive glucagon-like peptide-1 responses. J Clin Endocrinol Metab. 2016;101(5):2076-2083.
35. Watanabe M, Houten SM, Mataki C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006;439(7075):484-489.
36. Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89(1):147-191.
37. Parker HE, Wallis K, le Roux CW, et al. Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion. Br J Pharmacol. 2012;165(2):414-423.
38. Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009;10(3):167-177.
39. Potthoff MJ, Potts A, He T, et al. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. Am J Physiol. 2013;304(4):G371-G380.
40. Scarpello JH, Hodgson E, Howlett HC. Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus. Diabet Med. 1998;15(8):651-656.
41. Napolitano A, Miller S, Nicholls AW, et al. Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLoS ONE. 2014;9(7):e100778.
42. Sum CF, Webster JM, Johnson AB, et al. The effect of intravenous metformin on glucose metabolism during hyperglycaemia in type 2 diabetes. Diabet Med. 1992;9(1):61-65.
43. Buse JB, DeFronzo RA, Rosenstock J, et al. The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care. 2016;39(2):198-205.
44. de la Cuesta-Zuluaga J, Mueller NT, Corrales-Agudelo V, et al. Metformin is associated with higher relative abundance of mucin-degrading akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut. Diabetes Care. 2017;40(1):54-62.
45. Caspary WF, Zavada I, Reimold W, et al. Alteration of bile acid metabolism and vitamin-B12-absorption in diabetics on biguanides. Diabetologia. 1977;13(3):187-193.
46. Carter D, Howlett HC, Wiernsperger NF, et al. Effects of metformin on bile salt transport by monolayers of human intestinal Caco-2 cells. Diabetes Obes Metab. 2002;4(6):424-427.
47. Rohde U, Hansen M, Brønden A, et al. Gallbladder emptying and single-dose metformin elicit robust and additive glucagon-like peptide-1 responses II. EASD, Abstract #532; 2014; September 15-19, Vienna, Austria.
48. Wu Y, Aquino CJ, Cowan DJ, et al. Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes. J Med Chem. 2013;56(12):5094-5114.
49. Chen L, Yao X, Young A, et al. Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes. Am J Physiol. 2012;302(1):E68-E76.
50. Simren M, Bajor A, Gillberg PG, et al. Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation – a double-blind study. Aliment Pharmacol Ther. 2011;34(1):41-50.
51. Rudling M, Camilleri M, Graffner H, et al. Specific inhibition of bile acid transport alters plasma lipids and GLP-1. BMC Cardiovasc Disord. 2015;15:75.
52. Russell DW. Fifty years of advances in bile acid synthesis and metabolism. J Lipid Res. 2009;50(suppl):S120-S125.
53. Prawitt J, Caron S, Staels B. Glucose-lowering effects of intestinal bile acid sequestration through enhancement of splanchnic glucose utilization. Trends Endocrinol Metab. 2014;25(5):235-244.
54. Bays HE, Goldberg RB, Truitt KE, et al. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med. 2008;168(18):1975-1983.
55. Beysen C, Murphy EJ, Deines K, et al. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia. 2012;55(2):432-442.
56. Davidson MH, Rooney M, Pollock E, et al. Effect of colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose. J Clin Lipidol. 2013;7(5):423-432.
57. Fonseca VA, Rosenstock J, Wang AC, et al. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care. 2008;31(8):1479-1484.
58. Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med. 1994;121(6):416-422.
59. Goldberg RB, Fonseca VA, Truitt KE, et al. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med. 2008;168(14):1531-1540.
60. Goldfine AB, Fonseca VA, Jones MR, et al. Long-term safety and tolerability of colesevelam HCl in subjects with type 2 diabetes. Horm Metab Res. 2010;42(1):23-30.
61. Handelsman Y, Goldberg RB, Garvey WT, et al. Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study. Endocr Pract. 2010;16(4):617-628.
62. Henry RR, Aroda VR, Mudaliar S, et al. Effects of colesevelam on glucose absorption and hepatic/peripheral insulin sensitivity in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012;14(1):40-46.
63. Rosenstock J, Hernandez-Triana E, Handelsman Y, et al. Initial combination therapy with metformin plus colesevelam in drug-naive Hispanic patients with early type 2 diabetes. Postgrad Med. 2012;124(4):7-13.
64. Schwartz SL, Lai YL, Xu J, et al. The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study. Metab Syndr Relat Disord. 2010;8(2):179-188.
65. Smushkin G, Sathananthan M, Piccinini F, et al. The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes. Diabetes. 2013;62(4):1094-1101.
66. Vega GL, Dunn FL, Grundy SM. Effect of colesevelam hydrochloride on glycemia and insulin sensitivity in men with the metabolic syndrome. Am J Cardiol. 2011;108(8):1129-1135.
67. Yamakawa T, Takano T, Utsunomiya H, et al. Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endocr J. 2007;54(1):53-58.
68. Zieve FJ, Kalin MF, Schwartz SL, et al. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther. 2007;29(1):74-83.
69. Hansen M, Sonne DP, Mikkelsen KH, et al. Bile acid sequestrants for glycemic control in patients with type 2 diabetes: a systematic review with meta-analysis of randomized controlled trials. J Diabetes Complications. 2017, doi: 10.1016/j.jdiacomp.2017.01.011.
70. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2016 executive summary. Endocr Pract. 2016;22(1):84-113.
71. Pharmacologic approaches to glycemic treatment. Diabetes Care. 2017;40(suppl 1):S64-S74.
72. Christensen DH, Rungby J, Thomsen RW. Nationwide trends in glucose-lowering drug use, Denmark, 1999–2014. Clin Epidemiol. 2016;8:381-387.
73. Lipska KJ, Yao X, Herrin J, et al. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Diabetes Care. 2017;40(4):468-475.
74. Marina AL, Utzschneider KM, Wright LA, et al. Colesevelam improves oral but not intravenous glucose tolerance by a mechanism independent of insulin sensitivity and beta-cell function. Diabetes Care. 2012;35(5):1119-1125.